Max Healthcare has successfully obtained approval from the National Company Law Tribunal (NCLT) for the merger between its wholly-owned subsidiaries, Crosslay Remedies Limited (CRL) and Jaypee Healthcare Limited (JHL). The approval, announced on November 7, 2025, follows the Board of Directors' decision on March 21, 2025, to pursue a Scheme of Amalgamation under the Companies Act, 2013. The merger is effective from the appointed date of October 5, 2024, and was communicated to the stock exchanges under the relevant regulations.

The NCLT's sanctioning of the merger follows a comprehensive review process, including a First Motion Application submitted by the companies, which sought to bypass the need for separate meetings of shareholders and creditors. The tribunal had previously granted this request in July 2025, allowing the process to proceed without extensive delays. In compliance with regulatory requirements, notices regarding the merger were published in major national dailies, and statutory authorities were notified, ensuring transparency throughout the merger process.

As part of the merger, the Scheme includes provisions addressing various liabilities, including those related to civil and consumer disputes amounting to Rs. 2,523 lakhs as of March 31, 2025. The merged entity is expected to manage these liabilities effectively, as outlined in the Scheme's detailed clauses. This strategic move is anticipated to enhance operational efficiencies and strengthen the financial position of Max Healthcare, reinforcing its commitment to delivering quality healthcare services across India.